Fig. 3. Atractylodin ameliorates obesity and lipogenesis in HFD-fed mice. (A) Molecular structure of atractylodin. (B) Schematic of the experimental procedure to evaluate the role of atractylodin (AT) in HFD-induced MASLD in mice (n=8-9, each group). (C) Mouse body weight. (D) White adipose tissue (WAT) weight of mice. (E) Serum triglyceride and total cholesterol levels. (F) Serum ALT and AST levels. (G) Representative H&E and Oil red O (ORO) staining images. Scale bar (H&E): 100 μm, scale bar (ORO): 60 μm. (H) The quantification of Oil red O staining (% of tissue area). (I) Liver weight. Data are presented as mean ± SEM (n=8-9). Statistical analysis was performed using one-way ANOVA with Tukey’s post-hoc test. *p<0.05, **p<0.01: compared with ND+Veh; #p<0.05, ##p<0.01: compared with HFD+Veh.
© Biomolecules & Therapeutics
